These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 28638790)

  • 1. Evolving role of Sorafenib in the management of hepatocellular carcinoma.
    Ziogas IA; Tsoulfas G
    World J Clin Oncol; 2017 Jun; 8(3):203-213. PubMed ID: 28638790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Goals and targets for personalized therapy for HCC.
    Couri T; Pillai A
    Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in multidisciplinary management of hepatocellular carcinoma.
    Gomaa AI; Waked I
    World J Hepatol; 2015 Apr; 7(4):673-87. PubMed ID: 25866604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
    Gish RG; Finn RS; Marrero JA
    Clin Adv Hematol Oncol; 2013 Apr; 11 Suppl 5():1-22; quiz 2 p following p22. PubMed ID: 23881427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapy of hepatocellular carcinoma: are we making progress?
    Roxburgh P; Evans TR
    Adv Ther; 2008 Nov; 25(11):1089-104. PubMed ID: 18972075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locoregional and systemic therapy for hepatocellular carcinoma.
    Gbolahan OB; Schacht MA; Beckley EW; LaRoche TP; O'Neil BH; Pyko M
    J Gastrointest Oncol; 2017 Apr; 8(2):215-228. PubMed ID: 28480062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
    Gish RG; Finn RS; Marrero JA
    Gastroenterol Hepatol (N Y); 2013 Apr; 9(4 Suppl 2):1-24. PubMed ID: 24872793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
    Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
    BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical treatment of hepatocellular carcinoma.
    Granito A; Bolondi L
    Mediterr J Hematol Infect Dis; 2009 Dec; 1(3):e2009021. PubMed ID: 21415957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
    Choi JY
    Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving therapies in the treatment of hepatocellular carcinoma.
    Spangenberg HC; Thimme R; Blum HE
    Biologics; 2008 Sep; 2(3):453-62. PubMed ID: 19707376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma.
    Wang CH; Wey KC; Mo LR; Chang KK; Lin RC; Kuo JJ
    Asian Pac J Cancer Prev; 2015; 16(9):3595-604. PubMed ID: 25987009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives.
    Hsu CH; Shen YC; Shao YY; Hsu C; Cheng AL
    J Hepatocell Carcinoma; 2014; 1():85-99. PubMed ID: 27508178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hepatocellular carcinoma: beyond international guidelines.
    Colombo M; Sangiovanni A
    Liver Int; 2015 Jan; 35 Suppl 1():129-38. PubMed ID: 25529098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment.
    Yegin EG; Oymaci E; Karatay E; Coker A
    Hepatobiliary Pancreat Dis Int; 2016 Jun; 15(3):234-56. PubMed ID: 27298100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of NK-based immunotherapy and sorafenib against hepatocellular carcinoma.
    Yang J; Eresen A; Scotti A; Cai K; Zhang Z
    Am J Cancer Res; 2021; 11(2):337-349. PubMed ID: 33575075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events of sorafenib in hepatocellular carcinoma treatment.
    Pang Y; Eresen A; Zhang Z; Hou Q; Wang Y; Yaghmai V; Zhang Z
    Am J Cancer Res; 2022; 12(6):2770-2782. PubMed ID: 35812068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current systemic treatment of hepatocellular carcinoma: A review of the literature.
    Chen KW; Ou TM; Hsu CW; Horng CT; Lee CC; Tsai YY; Tsai CC; Liou YS; Yang CC; Hsueh CW; Kuo WH
    World J Hepatol; 2015 Jun; 7(10):1412-20. PubMed ID: 26052386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.